These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33295707)

  • 1. [Therapeutic options to reduce arterial stiffness in chronic kidney disease].
    Sessa C; Castellino P; Battaglia GG; Fatuzzo P; Gaudio A; Granata A; Lentini P; Marcantoni C; Morale W; Musso S; Rapisarda F; Santoro D; Zanoli L;
    G Ital Nefrol; 2020 Dec; 37(6):. PubMed ID: 33295707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vascular dysfunction in Cardiorenal Syndrome type 4].
    Sessa C; Granata A; Gaudio A; Xourafa A; Malatino L; Lentini P; Fatuzzo P; Rapisarda F; Castellino P; Zanoli L
    G Ital Nefrol; 2020 Feb; 37(1):. PubMed ID: 32068357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arterial Stiffness in the Heart Disease of CKD.
    Zanoli L; Lentini P; Briet M; Castellino P; House AA; London GM; Malatino L; McCullough PA; Mikhailidis DP; Boutouyrie P
    J Am Soc Nephrol; 2019 Jun; 30(6):918-928. PubMed ID: 31040188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease.
    Rossi M; Campbell KL; Johnson DW; Stanton T; Vesey DA; Coombes JS; Weston KS; Hawley CM; McWhinney BC; Ungerer JP; Isbel N
    Arch Med Res; 2014 May; 45(4):309-17. PubMed ID: 24751327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.
    Guo J; Lu L; Hua Y; Huang K; Wang I; Huang L; Fu Q; Chen A; Chan P; Fan H; Liu ZM; Wang BH
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H1-H13. PubMed ID: 28411233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic kidney disease-a cardiovascular high-risk constellation].
    Speer T; Schunk SJ; Fliser D
    Internist (Berl); 2020 Apr; 61(4):340-348. PubMed ID: 31578597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease.
    Karras A; Haymann JP; Bozec E; Metzger M; Jacquot C; Maruani G; Houillier P; Froissart M; Stengel B; Guardiola P; Laurent S; Boutouyrie P; Briet M;
    Hypertension; 2012 Dec; 60(6):1451-7. PubMed ID: 23090769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial stiffness and pulse pressure in CKD and ESRD.
    Briet M; Boutouyrie P; Laurent S; London GM
    Kidney Int; 2012 Aug; 82(4):388-400. PubMed ID: 22534962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
    Filipska I; Winiarska A; Knysak M; Stompór T
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Uremic Toxins to Prevent Peripheral Vascular Complications in Chronic Kidney Disease.
    Wu CL; Tarng DC
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33419312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of aortic stiffness in end-stage renal disease and diabetes: implication for hypertension management.
    Yannoutsos A; Bahous SA; Safar ME; Blacher J
    J Hypertens; 2018 Jun; 36(6):1237-1246. PubMed ID: 29300243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD.
    Pieniazek A; Bernasinska-Slomczewska J; Gwozdzinski L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
    Lau WL; Savoj J; Nakata MB; Vaziri ND
    Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients.
    Georgianos PI; Sarafidis PA; Lasaridis AN
    Curr Vasc Pharmacol; 2015; 13(2):229-38. PubMed ID: 24007427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.
    Rossi M; Campbell K; Johnson D; Stanton T; Pascoe E; Hawley C; Dimeski G; McWhinney B; Ungerer J; Isbel N
    Nutr Metab Cardiovasc Dis; 2014 Sep; 24(9):1035-42. PubMed ID: 24880738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aortic stiffness and central systolic pressure are associated with ambulatory orthostatic BP fall in chronic kidney disease.
    Kirkham FA; Rankin P; Parekh N; Holt SG; Rajkumar C
    J Nephrol; 2020 Apr; 33(2):317-324. PubMed ID: 31598911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.
    Wojtaszek E; Oldakowska-Jedynak U; Kwiatkowska M; Glogowski T; Malyszko J
    Oxid Med Cell Longev; 2021; 2021():6651367. PubMed ID: 33628373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease.
    Gil-Ortega M; Vega-Martín E; Martín-Ramos M; González-Blázquez R; Pulido-Olmo H; Ruiz-Hurtado G; Schulz A; Ruilope LM; Kolkhof P; Somoza B; Kreutz R; Fernández-Alfonso MS
    Am J Nephrol; 2020; 51(4):294-303. PubMed ID: 32088716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uremic Toxins and Cardiovascular System.
    Valkenburg S; Glorieux G; Vanholder R
    Cardiol Clin; 2021 Aug; 39(3):307-318. PubMed ID: 34247746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial Stiffness in Chronic Kidney Disease and End-Stage Renal Disease.
    London GM
    Blood Purif; 2018; 45(1-3):154-158. PubMed ID: 29478047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.